Pharma Focus Asia

Arcellx and Kite Reveal an Extended Collaboration Within Their Strategic Partnership

Thursday, November 16, 2023

Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, initially disclosed in December 2022. In this development, Kite has opted to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, designed for multiple myeloma, with a focus on BCMA. Furthermore, the collaboration scope has widened to include lymphomas for Arcellx's CART-ddBCMA.

Arcellx, expressed enthusiasm about the rapid progress of the partnership and the potential of their innovative synthetic binder, the D-Domain, in creating a new category of CAR T therapies. The deepened collaboration involves Kite's investment in ACLX-001 and increased support for CART-ddBCMA, aiming to extend Arcellx's cash position until 2027.

Kite, highlighted the positive momentum of the CART-ddBCMA program and the extension of the collaboration into areas of significant unmet medical need. Kite's increased engagement aims to advance CART-ddBCMA, strengthen the multiple myeloma pipeline, and explore possibilities in lymphoma.

Arcellx will receive a $200 million equity investment, extending its financial runway. Gilead's estimated ownership in Arcellx will be 13%. The transaction includes an $85 million upfront non-dilutive cash payment, potential milestone payments, and is expected to close by the end of 2023, pending regulatory approvals.

The collaboration between Arcellx and Kite is centered on co-developing and co-commercializing CART-ddBCMA for relapsed or refractory multiple myeloma. The asset utilizes the D-Domain to enhance target specificity and binding affinity. Kite will lead commercialization efforts outside the U.S.

The transaction is anticipated to impact Gilead's 2023 EPS by approximately $0.09-$0.11 per share, and legal counsel to Arcellx is provided by Wilson Sonsini Goodrich & Rosati.



magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference